Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Half-life extension using serum albumin-binding DARPin® domains.
Steiner D, Merz FW, Sonderegger I, Gulotti-Georgieva M, Villemagne D, Phillips DJ, Forrer P, Stumpp MT, Zitt C, Binz HK. Steiner D, et al. Among authors: zitt c. Protein Eng Des Sel. 2017 Sep 1;30(9):583-591. doi: 10.1093/protein/gzx022. Protein Eng Des Sel. 2017. PMID: 29088432
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. Baird RD, et al. Among authors: zitt c. J Clin Oncol. 2021 Jan 10;39(2):145-154. doi: 10.1200/JCO.20.00596. Epub 2020 Dec 10. J Clin Oncol. 2021. PMID: 33301375 Free PMC article. Clinical Trial.
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.
Rothenberger S, Hurdiss DL, Walser M, Malvezzi F, Mayor J, Ryter S, Moreno H, Liechti N, Bosshart A, Iss C, Calabro V, Cornelius A, Hospodarsch T, Neculcea A, Looser T, Schlegel A, Fontaine S, Villemagne D, Paladino M, Schiegg D, Mangold S, Reichen C, Radom F, Kaufmann Y, Schaible D, Schlegel I, Zitt C, Sigrist G, Straumann M, Wolter J, Comby M, Sacarcelik F, Drulyte I, Lyoo H, Wang C, Li W, Du W, Binz HK, Herrup R, Lusvarghi S, Neerukonda SN, Vassell R, Wang W, Adler JM, Eschke K, Nascimento M, Abdelgawad A, Gruber AD, Bushe J, Kershaw O, Knutson CG, Balavenkatraman KK, Ramanathan K, Wyler E, Teixeira Alves LG, Lewis S, Watson R, Haeuptle MA, Zürcher A, Dawson KM, Steiner D, Weiss CD, Amstutz P, van Kuppeveld FJM, Stumpp MT, Bosch BJ, Engler O, Trimpert J. Rothenberger S, et al. Among authors: zitt c. Nat Biotechnol. 2022 Dec;40(12):1845-1854. doi: 10.1038/s41587-022-01382-3. Epub 2022 Jul 21. Nat Biotechnol. 2022. PMID: 35864170 Free PMC article.
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.
Stojcheva N, Gladman S, Soergel M, Zitt C, Drake R, Lockett T, Marchand C, Fustier P, Stavropoulou V, Fernandez E, Pettigiani NL, Watkins K, Puri A, Watson R, Legenne P, Stumpp MT, Boyce M. Stojcheva N, et al. Among authors: zitt c. Br J Clin Pharmacol. 2023 Jul;89(7):2295-2303. doi: 10.1111/bcp.15747. Epub 2023 May 8. Br J Clin Pharmacol. 2023. PMID: 37057679 Clinical Trial.
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Grübler Y, Marpakwar R, Looser T, Spitzli P, Herzog C, Villemagne D, Schiegg D, Abduli L, Iss C, Neculcea A, Franchini M, Lekishvili T, Ragusa S, Zitt C, Kaufmann Y, Auge A, Hänggi M, Ali W, Frasconi TM, Wullschleger S, Schlegel I, Matzner M, Lüthi U, Schlereth B, Dawson KM, Kirkin V, Ochsenbein AF, Grimm S, Reschke N, Riether C, Steiner D, Leupin N, Goubier A. Bianchi M, et al. Among authors: zitt c. Cancer Immunol Res. 2024 Apr 29. doi: 10.1158/2326-6066.CIR-23-0692. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38683145 Free article.
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Fischer S, Götze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. Fischer S, et al. Among authors: zitt c. JCO Precis Oncol. 2022 Nov;6:e2200006. doi: 10.1200/PO.22.00006. JCO Precis Oncol. 2022. PMID: 36331248 Free PMC article. No abstract available.
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
Prins MLM, van der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC. Prins MLM, et al. Among authors: zitt c. Br J Clin Pharmacol. 2023 Mar;89(3):1105-1114. doi: 10.1111/bcp.15560. Epub 2022 Oct 24. Br J Clin Pharmacol. 2023. PMID: 36214216 Free PMC article. Clinical Trial.
Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.
Thur Y, Bhalerao A, Munshi Z, Pansare N, Mann K, Hanauer G, Kley HP, Nappe S, Weiss-Haljiti C, Ostermann C, Zitt C, Schaefer M, Mondal D, Ali Siddiki A, Armugam V, Gudaghe V, Gupta M, Rayudu P, Dautzenberg FM, Das Sarma K. Thur Y, et al. Among authors: zitt c. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7314-21. doi: 10.1016/j.bmcl.2012.10.087. Epub 2012 Oct 25. Bioorg Med Chem Lett. 2012. PMID: 23147076
21 results